3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Uterine Cervical Neoplasms
2
Interventions
pembrolizumab
223
Carboplatin
219
Cisplatin
206
Paclitaxel
182
Gemcitabine
149
Docetaxel
127
Capecitabine
115
Pemetrexed
102
Dexamethasone
102
Cyclophosphamide
102
Specimen Handling
99
Magnetic Resonance Spectroscopy
97
Oxaliplatin
96
Radiotherapy
95
Doxorubicin
92
Fluorouracil
88
Bevacizumab
84
Nivolumab
74
Leucovorin
73
Rituximab
71
Vincristine
68
durvalumab
66
Lenalidomide
64
Radiation
62
Etoposide
62
atezolizumab
61
Irinotecan
61
130-nm albumin-bound paclitaxel
58
Prednisone
57
Letrozole
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
tisotumab vedotin
×
1 year
×
Clear all
NCT06459180
2026-05-27
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
686 enrolled
NCT04697628
2026-02-24
innovaTV 301
Seagen Inc.
Phase 3
Completed
502 enrolled
18 charts
1 FDA